Asian Pacific Journal of Cancer Prevention

  • 제16권13호
  • /
  • Pages.5219-5223
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Genotyping of Peroxisome Proliferator-Activated Receptor gamma in Iranian Patients with Helicobacter pylori Infection

  • Goudarzi, Hossein (Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Science) ;
  • Seyedjavadi, Sima Sadat (Department of Pharmaceutical Biotechnology, Pasteur institute) ;
  • Fazeli, Maryam (Department of Virology, Faculty of Medicine, Tarbiat Modares University) ;
  • Azad, Mehdi (Department of Medical laboratory sciences, School of Paramedicine, Qazvin University of Medical Sciences) ;
  • Goudarzi, Mehdi (Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Science)
  • 발행 : 2015.08.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Helicobacter pylori (H. pylori) infection as a serious problem in both adults and children can induce chronic gastritis, peptic ulcer disease (PUD), and possibly gastric cancer. The aim of the current study was to survey antibiotic resistance and also to determine influence of PPAR$\gamma$ polymorphism in patients with H. pylori infection. During an 11-month-period, 98 H. pylori isolates were collected from 104 biopsy specimens. In vitro susceptibility of H. pylori isolates to 4 antimicrobial agents metronidazole, clarithromycin, amoxicillin and tetracycline were assessed by quantitative method according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline. PPAR$\gamma$ polymorphism was determined using polymerase chain reaction-restriction fragment length polymorphism assay. The frequency of H. pylori infection in our study was 94.2%. In vitro susceptibility data showed that highest level of resistance was related to metronidazole (66.3%), and the majority of H. pylori isolates were highly susceptible to amoxicillin and tetracycline (94.9% and 96.9%, respectively). Genotypic frequencies were 25.5% for CC (Pro12Pro), 40.8% for GC (Pro12Ala) and 33.7% for GG (Ala12Ala). In our study, CG genotype had highest distributions among infected patients with H. pylori. The study suggests that the PPAR-$\gamma$ Pro12Ala polymorphism could be evaluated as a potential genetic marker for susceptibility to gastric cancer in the presence of H. pylori infection.

키워드

참고문헌

  1. Alvarez A, Moncayo Ji, Santacruz Jj, et al (2009). Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrobial Agents Chemotherapy, 53, 4022-4. https://doi.org/10.1128/AAC.00145-09
  2. Baglan Ph, Bozdayi G, Ozkan M, et al (2006). Clarithromycin resistance prevalence and iceA gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. J Microbiol-Seoul, 44, 409.
  3. Bazargani A, Khoramrooz Ss, Kamali-Sarvestani E, et al (2010). Association between peroxisome proliferator-activated receptor-${\gamma}$ gene polymorphism (Pro12Ala) and Helicobacter pylori infection in gastric carcinogenesis. Scandinavian J gastroenterol, 45, 1162-7. https://doi.org/10.3109/00365521.2010.499959
  4. Canbay E, Kurnaz O, Canbay B, et al (2012). PPAR-gamma Pro12Ala polymorphism and gastric cancer risk in a Turkish population. Asian Pac J Cancer Prev, 13, 5875-8. https://doi.org/10.7314/APJCP.2012.13.11.5875
  5. Chisholm S, Teare E, Davies K, et al (2007). Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill, 12, 3-4.
  6. Eun Cs, Han Ds, Park Jy, et al (2003). Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J gastroenterol, 38, 436-441. https://doi.org/10.1007/s00535-002-1079-2
  7. Frenck Jr, Rw, Clemens J (2003). Helicobacter in the developing world. Microb Infect, 5, 705-13. https://doi.org/10.1016/S1286-4579(03)00112-6
  8. Gerrits Mm, Van Vliet Ah, Kuipers Ej, et al (2006). Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infectious Diseases, 6, 699-709. https://doi.org/10.1016/S1473-3099(06)70627-2
  9. Goto Y, Hagikura S, Katsuda N, et al (2011). AC to T polymorphism of urokinase plasminogen activator (P141L) is associated with Helicobacter pylori infection. Asian Pac J Cancer Prev, 12, 803-6.
  10. Greene M, Blumberg B, Mcbride O, et al (1994). Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene expression, 4, 281-99.
  11. He W (2009). PPAR${\gamma}$2Pro12Ala polymorphism and human health. PPAR research, 1-15.
  12. Jing Ym, Guo Sx, Zhang Xp, et al (2012). Association between C1019T polymorphism in the connexin 37 gene and Helicobacter pylori infection in patients with gastric cancer. Asian Pac J Cancer Prev, 13, 2363-7. https://doi.org/10.7314/APJCP.2012.13.5.2363
  13. Kim Jj, Reddy R, Lee M, et al (2001). Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemot, 47, 459-61. https://doi.org/10.1093/jac/47.4.459
  14. Konturek Pc, Kania J, Kukharsky V, et al (2004). Implication of peroxisome proliferator-activated receptor. GAMMA. and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. J Pharmacol Sci, 96, 134-43. https://doi.org/10.1254/jphs.FPJ04016X
  15. Liao S, Zeng Z, Leung W, et al (2006). Peroxisome proliferatoractivated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment Pharmacol Therap, 23, 289-94. https://doi.org/10.1111/j.1365-2036.2006.02739.x
  16. Ling T, Leung W, Lee C, et al (2002). The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001). Helicobacter, 7, 327-8. https://doi.org/10.1046/j.1523-5378.2002.00101_1.x
  17. Mansour B, Burucoa C, Zribi M, et al (2010). Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Ann Clin Microbiol Antimicrobials, 9, 22. https://doi.org/10.1186/1476-0711-9-22
  18. Marshall Bj, Armstrong J, Francis G, et al (1987). Antibacterial action of bismuth in relation to campylobacter pyloridis colonization and gastritis. Digestion, 37, 16-30. https://doi.org/10.1159/000199555
  19. Megraud F, Coenen S, Versporten A, et al (2013). Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut, 62, 34-42. https://doi.org/10.1136/gutjnl-2012-302254
  20. Michalik L, Desvergne B, Wahli W, et al (2004). Peroxisomeproliferator-activated receptors and cancers: complex stories. Nat Rev Cancer, 4, 61-70. https://doi.org/10.1038/nrc1254
  21. Parsonnet j, friedman gd, vandersteen DP, et al (1991). Helicobacter pylori infection and the risk of gastric carcinoma. New England J Med, 325, 1127-31. https://doi.org/10.1056/NEJM199110173251603
  22. Prasad K, Saxena A, Ghoshal U, et al (2008). Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease. Ann Oncol, 19, 1299-303. https://doi.org/10.1093/annonc/mdn055
  23. Shibata T, Tahara T, Yonemura J, et al (2010). The G-protein ${\beta}$3 polymorphism is associated with diffuse type gastric cancer in Japanese. Asian Pac J Cancer Prev, 11, 1195-9.
  24. Tahara T, Arisawa T, Shibata T, et al (2008). Influence of peroxisome proliferator-activated receptor (PPAR) ${\gamma}$ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. Digestive Dis Sci, 53, 614-21. https://doi.org/10.1007/s10620-007-9944-8
  25. Tomatari Fh, Mobarez Am, Amini M, et al (2010). Helicobacter pylori resistance to metronidazole and clarithromycin in dyspeptic patients in Iran. Iranian Red Crescent Med J, 12, 409-12.
  26. Torres J, Camorlinga-Ponce M, Perez-Perez G, et al (2001). Increasing multidrug resistance in Helicobacter pylori Strains isolated from children and adults in Mexico. J Clin Microb, 39, 2677-80. https://doi.org/10.1128/JCM.39.7.2677-2680.2001
  27. Uemura N, Okamoto S, Yamamoto S, et al (2001). Helicobacter pylori infection and the development of gastric cancer. New Eng J Med, 345, 784-9. https://doi.org/10.1056/NEJMoa001999
  28. Van Amsterdam K, Bart A, Van Der Ende A (2005). A Helicobacter pylori TolC efflux pump confers resistance to metronidazole. Antimicrob Agents Ch, 49, 1477-82. https://doi.org/10.1128/AAC.49.4.1477-1482.2005
  29. Van Doorn Lj, Glupczynski Y, Kusters Jg, et al (2001). Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Ch, 45, 1500-4. https://doi.org/10.1128/AAC.45.5.1500-1504.2001
  30. Vilaichone Rk, Panarat W, Aekpongpaisit S, et al (2014). Clinical characteristics and Helicobacter pylori status of gastric cancer in Thailand. Asian Pac J Cancer Prev, 15, 9005. https://doi.org/10.7314/APJCP.2014.15.20.9005
  31. Wheeldon T, Granstrom M, Hoang T, et al (2004). The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharm Therap, 19, 1315-21. https://doi.org/10.1111/j.1365-2036.2004.01959.x